A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Completed
Kyowa Hakko Kirin Company, Limited
Phase 2
2005-04-01
To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the
percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with
levodopa.
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Completed
Kyowa Kirin Co., Ltd.
Phase 2
2005-04-01
To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the
percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with
levodopa.
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
Completed
Kyowa Hakko Kirin UK, Ltd.
Phase 3
2004-10-01
This is a 1-year, open-label, long-term safety extension for patients who have completed
prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
Completed
Kyowa Kirin Pharmaceutical Development, Inc.
Phase 3
2004-10-01
This is a 1-year, open-label, long-term safety extension for patients who have completed
prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
Completed
Kyowa Kirin, Inc.
Phase 3
2004-10-01
This is a 1-year, open-label, long-term safety extension for patients who have completed
prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
